ABSTRACT
Family history is the standard indirect measure of inherited susceptibility in clinical care, while polygenic risk scores (PRS) have more recently demonstrated potential for more directly capturing genetic risk in many diseases. No studies have systematically compared how these overlap and complement each other across common diseases. Within FinnGen (N=306,418), we leverage family relationships, up to 50 years of nationwide registries, and genome-wide genotyping to examine the interplay of family history and genome-wide PRSs. We explore the dynamic for three types of family history across 24 common diseases: first- and second-degree family history, and parental causes of death. Covering a large proportion of the burden of non-communicable diseases in adults, we show that family history and PRS are independent and not interchangeable measures, but instead provide complementary information of inherited disease susceptibility. The PRSs explained on average 10% of the effect of first-degree family history, and first-degree family history 3% of PRSs, and PRS effects were independent of both early- and late-onset family history. The PRS stratified the risk similarly in individuals with and without family history. In most diseases, including coronary artery disease, glaucoma, and type 2 diabetes, a positive family history with a high PRS was associated with a considerably elevated risk, whereas a low PRS compensated completely for the risk implied by positive family history. This study provides a catalogue of risk estimates for both family history of disease and PRSs, and highlights opportunities for a more comprehensive way of assessing inherited disease risk across common diseases.
Competing Interest Statement
A.P. is a member of the Pfizer Genetics Scientific Advisory Panel. The remaining authors declare no competing interests.
Funding Statement
This work has been supported by Academy of Finland (grant number 331671 to N.M., 285380 to S.R., 128650 to A.P., 308248 to J.K.); Academy of Finland Center of Excellence in Complex Disease Genetics (grant number 312062 to S.R., 312074 to A.P., 312073 to J.K.); European Union Horizon 2020 research and innovation programme under grant agreement No 101016775; the Sigrid Juselius Foundation (to S.R. and A.P.); University of Helsinki HiLIFE Fellow grants 2017-2020 (to S.R.); The Finnish Innovation Fund Tekes (grant number 2273/31/2017 to E.W.); Foundation and the Horizon 2020 Research and Innovation Programme (grant number 667301 (COSYN) to A.P.); JVL was supported by Academy of Finland (grant number 311492) and Helsinki Institute of Life Science (H970).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/ 2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/2020, and THL/2364/ 14.02/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020, Findata THL/2364/14.02/2020 and Statistics Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data availability
The FinnGen data may be accessed through Finnish Biobanks’ FinBB portal (web link: www.finbb.fi, email: info.fingenious{at}finbb.fi). Download links for the GWAS summary statistics used for constructing are provided in Supplementary Table 1. The weights for our polygenic risk scores will be made are available at PGS Catalog (pgs-info{at}ebi.ac.uk), with the submitted data embargoed until publication and PGS Catalog identifiers reported in the final version of the manuscript.